AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT00235937
Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease
Phase 4
Completed
- Conditions
- Coronary Heart Disease
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 255
- Registration Number
- NCT00235950
- Locations
- 🇸🇪
Research Site, Örebro, Sweden
PreAsthmaControl (PAC)
Phase 4
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00234390
- Locations
- 🇩🇰
Research Site, Copenhagen, Denmark
Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 550
- Registration Number
- NCT00234377
- Locations
- 🇭🇺
Research Site, Szekesfehervar, Hungary
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
Phase 3
Terminated
- Conditions
- Non Small Cell Lung Carcinoma
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2011-05-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 490
- Registration Number
- NCT00234468
- Locations
- 🇮🇹
Research Site, Venezia-Mestre, Italy
IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer
Phase 1
Completed
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT00234416
- Locations
- 🇪🇸
Research Site, Valencia, Spain
A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00234403
- Locations
- 🇪🇸
Investigative Site, Zaragoza, Spain
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Brain NeoplasmsNon Small Cell Lung Cancer
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2009-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT00234442
- Locations
- 🇮🇹
Research Site, Rozzano, Italy
A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma
Phase 2
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 74
- Registration Number
- NCT00234429
- Locations
- 🇪🇸
Research Site, Valladolid, Spain
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
Phase 2
Withdrawn
- Conditions
- Head and Neck CancerCarcinoma, Squamous Cell
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT00233636
- Locations
- 🇮🇹
Research Site, Ragusa, Italy
© Copyright 2025. All Rights Reserved by MedPath